Skip to Content
Merck
All Photos(1)

Documents

SML3025

Sigma-Aldrich

BAY-784

≥98% (HPLC)

Synonym(s):

BAY-784, (2S)-N-[[3-Chloro-5-(trifluoromethyl)-2-pyridyl]methyl]-2-cyclopropyl-1-(4-fluorophenyl)sulfonyl-1′,1′-dioxo-spiro[indoline-3,4′-thiane]-5-carboxamide, (2S)-N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-2-cyclopropyl-1-[(4-fluorophenyl)sulfonyl]-1,2,2?,3?,5?,6?-hexahydro-spiro[3H-indole-3,4?-[4H]thiopyran]-5-carboxamide 1?,1?-dioxide, BAY 1214784, BAY-1214784

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C29H26ClF4N3O5S2
CAS Number:
Molecular Weight:
672.11
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -120 to -100°, c = 0.5 in chloroform-d

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

O=S(CCC1(C2=C(N3S(C4=CC=C(F)C=C4)(=O)=O)C=CC(C(NCC5=C(Cl)C=C(C(F)(F)F)C=N5)=O)=C2)[C@@H]3C6CC6)(CC1)=O

Biochem/physiol Actions

BAY-784 is an orally available, non-toxic, potent, and selective antagonist of human Gonadotropin-Releasing Hormone Receptor [hGnRH-R], which is potently active in other species including rate, dogs and cynomolgus monkey. It partially lowered plasma luteinizing hormone levels in humans. BAY-784 exhibits favorable drug metabolism and pharmacokinetic (DMPK) profile thus is suitable for in vivo studies.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Olaf Panknin et al.
Journal of medicinal chemistry, 63(20), 11854-11881 (2020-09-23)
The growth of uterine fibroids is sex hormone-dependent and commonly associated with highly incapacitating symptoms. Most treatment options consist of the control of these hormonal effects, ultimately blocking proliferative estrogen signaling (i.e., oral contraceptives/antagonization of human gonadotropin-releasing hormone receptor [hGnRH-R]

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service